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INTRODUCTION
Opportunistic infections (OIs) are the main cause of morbidity and mortality in patients with
HIV-1 infection throughout the world, particularly among patients who have not had access
to anti-retroviral therapy (ART) and other HIV care services. 1, 2, 3 Among patients taking
ART, OIs can present when the immune system starts to recover aka immune reconstitution
inflammatory syndrome (IRIS). 4, 5 Also, some patients do not have a sustained response to
ART due to lack of adherence to medications, development of drug resistance, or suboptimal
therapeutic regimens. 1 Therefore, OIs continue to cause substantial morbidity and mortality
even after initiation of ART.
The World Health Organization (WHO) developed HIV clinical staging criteria based on
OIs to standardize disease severity classification in the absence of virologic or immunologic
measurements. 6, 7 Diagnosis of WHO stage 4 conditions remains important in the ART era
in order to: 1) help determine timing of ART initiation, and 2) treat OIs to reduce morbidity
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and mortality. There are no published data from Kenya that quantify the burden of WHO
stage 4 conditions that persist in the ART era and continue to negatively impact patient
survival. We therefore set out to determine the prevalence and gender distribution of WHO
stage 4 conditions among patients enrolled in a large peri-urban HIV clinic in western
Kenya.
METHODS
We performed a retrospective review of adult patients who enrolled into care in a
comprehensive outpatient HIV clinic between March 2005 and July 2008, and analyzed the
frequency of WHO stage 4 conditions.
Setting
The Family AIDS Care and Education Services (FACES) program, a collaboration between
the Kenya Medical Research Institute (KEMRI) and University of California San Francisco
(UCSF), pioneered a family model of HIV prevention, care, and treatment in Nyanza
Province and Nairobi, Kenya.8 This study was conducted at Lumumba Health Centre
(LHC), which is one of FACES’ largest outpatient HIV clinics in Kisumu, Nyanza Province.
Nyanza Province has an HIV prevalence of 15.3%, which is more than twice the national
prevalence of 6.3%. 9 LHC has the capacity for on-site laboratory tests including complete
blood count, serum chemistries, CD4+ cell count assays, Rapid Plasma Reagin (RPR), and
serum cryptococcal antigen (sCrAg) testing. Tissue biopsies for cytology and chest
radiographs are available within Kisumu and are routinely paid for with program funds.
Additional tests such as ultrasound, computed tomography (CT) scans and endoscopy are
available, but coverage depends on the availability of extra program funds or the patients’
ability to pay. ART is available at no cost to patients who qualify based on WHO stage and/
or CD4 count, following the Kenya national guidelines.10 Patients attending LHC for HIV
care are staged according to WHO criteria as part of their enrollment assessment and
reassessed at every follow-up visit.
Data Sources
The HIV clinic at LHC has an electronic medical record system (EMRS) that captures
important patient-level demographic and clinical variables at each clinic visit. At every visit,
patient encounters are documented using standardized clinical forms, after which the
information is entered into the EMRS. Information collected using patient encounter forms
includes demographic characteristics such as age and gender, ART status, and clinical
variables such as WHO stage and staging criteria, and laboratory test results. In September
2009, we used the EMRS database to identify all adult patients (age >15 years old) who
enrolled into care between March 2005 and July 2008. Out of these newly enrolled patients,
we identified those with WHO stage 4 conditions at enrollment or subsequent visits. We
obtained data on CD4+ cell count at enrollment, gender, age, and status in care [dead, alive
in care, transferred out, or lost to follow-up (LFU)] at the time of data abstraction. The
patient files were reviewed to confirm diagnosis and abstract missing variables. For patients
who had not attended the clinic for three or more months, a community health worker
(CHW) called or attempted a home visit to determine their current status. If the CHW was
not able to locate them or receive a reliable report of their status, then they were classified as
LFU.
Statistical Methods
Data from the EMRS were exported into an Excel (Microsoft Inc, Redmond, WA)
spreadsheet. Data abstracted from manual chart reviews were entered into a standardized
data abstraction tool then transferred to the spreadsheet. Bivariate analysis was performed to
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examine the association between various WHO stage 4 conditions and age, gender, and
CD4+ cell count. Chi- square or Fishers exact tests were used for categorical variables, and
the student’s t-test was used to compare continuous variables. Data were analyzed using
STATA version 11.0 (StataCorp, College Station, TX). A value of p < 0.05 was considered
significant.
Ethical Considerations
The FACES program obtained ethical approval from the KEMRI Ethical Review Committee
and the UCSF Committee on Human Research to utilize routinely gathered retrospective
medical information for evaluation and dissemination purposes, including the data
abstracted for this study. To protect patient privacy, all data were de-identified and de-linked
with patient identifiers.
RESULTS
Of the 5,784 adult patients enrolled during the study period, 437 (7.6%) had a WHO stage 4
diagnosis during the study period at enrollment and follow up of which 260 (59.5%) were
females. Among all females enrolled into care, 6.7% had a WHO stage 4 diagnosis
compared to 9.3% among all enrolled men (p<0.001). The mean age of females was 34.7
years (SD: 9.0) compared to 37.2 years (SD: 8.4) for men. The median CD4+ cell count at
enrollment was 84 cells/μL (IQR: 31, 191) and 325/423 (76.8%) patients had a baseline
CD4+ cell count below 200 cells/uL. Of the 437 patients with WHO stage 4 diagnoses, 427
(97.7%) patient files were found and reviewed. These 427 patients contributed 483 WHO
stage 4 conditions to the analysis as 56 patients had two conditions.
Out of the 427 patients, 367 (85.9%) were initiated on ART during the study period; 346 of
the 367 who had been initiated on ART had dates recorded for ART initiation and the WHO
stage 4 diagnosis. Of the 346 patients, 127 (36.7%) had started on ART before the WHO
stage 4 diagnosis, 34 (9.8%) started ART on the day of their WHO stage 4 diagnosis and
185 (53.5%) started ART after the WHO stage 4 diagnosis. Of the 127 patients diagnosed
with a WHO stage 4 diagnoses after ART initiation, 78 (61.4%) had the diagnosis within six
months of ART initiation.
At the end of the study period, 253 (59.2%) were active in care, 60 (14.0%) were confirmed
dead, 28 (6.6%) had transferred out to other HIV clinics, and 86 (20.1%) were LFU.
The most common conditions in order of frequency were esophageal candidiasis, extra
pulmonary tuberculosis, HIV wasting syndrome, Kaposi’s sarcoma (KS), and cryptococcal
meningitis (Table 1). Esophageal candidiasis was significantly more frequent among women
with WHO stage 4 conditions than men (p=0.029), and KS was more frequent among men
(p<0.001). When analyzing frequency of WHO stage 4 conditions based on a CD4+ cut-off
of 100 cell/μL, only esophageal candidiasis was significantly associated with CD4+ count ≤
100 cell/μL (p=0.003) (data not shown).
Among the 56 patients with more than one WHO stage 4 condition, the most frequent
combination was esophageal candidiasis and HIV wasting syndrome (15 (26.8%)). Pleural
effusion was the most frequent type of extra pulmonary tuberculosis (58.8%), while
cutaneous KS involving the lower limbs was the most frequent presentation of KS (64.4%)
(data not shown).
Those initially diagnosed with esophageal candidiasis, HIV wasting syndrome, KS, and
extra-pulmonary tuberculosis contributed most to the number of deaths (data not shown).
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Our study found that 7.6% of our patients had a WHO stage 4 diagnoses. We also found a
higher proportion of WHO stage 4 conditions among men compared to women enrolled in
care, a finding consistent with two other studies in East Africa which found that at
enrolment, men were more immunocompromised compared to women. 11, 12 This could be
attributed to the poor health seeking behavior of men delaying or avoiding enrollment in
care even after they know their HIV status.13,14,15
We found that esophageal candidiasis was more common among women. This gender
distribution is consistent with other HIV-positive cohorts.16,17 KS was more common
among men, which is consistent with studies among non-HIV positive cohorts, 18,19 and
among HIV-positive patients.16
The major limitation of our study was reliance on clinical diagnosis for many of the WHO
stage 4 conditions of interest. Although this may contribute to an underestimation or
overestimation of the disease prevalence for certain conditions, it is representative of how
patients are diagnosed and treated in similar resource-limited settings.
This study identified the most common WHO stage 4 conditions in a peri-urban HIV clinic
in western Kenya. These findings can provide guidance to HIV programs for prioritizing
resources to ensure adequate diagnosis and management of these conditions.
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Table 1
Frequency of WHO stage 4 conditions by sex in a cohort of adults enrolled in outpatient HIV care in Kisumu,
Kenya
WHO Stage 4 Conditions Total Female (n=286 WHO stage 4
conditions among 253 women)
Male (n=197 WHO stage 4 conditions
among 174 men)
p-Value
Esophageal candidiasis 184 120 (47.7%) 64 (36.8%) 0.029
Extra pulmonary tuberculosis 94 52 (20.6%) 42 (24.1%) 0.378
HIV wasting syndrome 67 45 (17.8%) 22 (12.6%) 0.151
Kaposi’s sarcoma 49 14 (5.5%) 35 (20.1%) <0.001
Cryptococcal meningitis 25 14 (5.5%) 11 (6.3%) 0.733
Pneumocystis jirovecii pneumonia 23 15 (5.9%) 8 (4.6%) 0.549
Cervical cancer* 6 6 (2.4%) N/A N/A
Others OIs† 35 20 (7.9%) 15 (8.6%) 0.791
*
For cervical cancer the n only applies for the number of women in the study
†
Other OIs include: Central nervous system toxoplasmosis: 14 (2.9%); genital herpes simplex virus infection: 8 (1.7%); HIV encephalopathy: 8
(1.7%); cytomegalovirus (CMV) infection: 1 (0.2%); mycobacterium avium complex (MAC): 1 (0.2%); progressive multifocal
leukoencephalopathy (PML): 1 (0.2%); and lymphoma: 1 (0.2%)
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